On June 26, 2025, Altimmune, Inc. announced positive results from its Phase 2b IMPACT trial of pemvidutide, demonstrating that 59.1% and 52.1% of participants achieved resolution of metabolic dysfunction-associated steatohepatitis (MASH) with two doses respectively, significantly higher than the 19.1% in the placebo group (p<0.0001). The trial involved 212 participants and showed favorable safety, with notable weight loss: 5.0% for 1.2 mg and 6.2% for 1.8 mg doses compared to 1.0% for placebo (p<0.001).